Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer appoints former J&J executive to lead ... 2025 UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older Britain's health regulator said on Friday it has approved ...

The CDC encourages doctors to vaccinate babies and adults over 60 years old, with two RSV vaccines for seniors, GSK’s Arexvy (88% effective) and Pfizer’s Abrysvo(85% effective), currently ...

Investigators randomly assigned participants in the United States and Japan in a 1:1 ratio to receive one dose of Pfizer’s bivalent (two-strain) RSV Prefusion F (RSVpreF) vaccine (Abrysvo ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...